Dyne Therapeutics
A Co-Op position at Dyne Therapeutics for the Oligonucleotide Chemistry team focusing on RNA therapeutics. The role involves synthesizing and characterizing oligonucleotides to support research in treating neuromuscular diseases.
Headquarters
Waltham, Massachusetts, United States
Company Size
51-200 employees
Founded
2018
Dyne Therapeutics is a biotechnology company developing nucleic acid–based therapies for genetically driven neuromuscular diseases. Leveraging its proprietary FORCE™ platform, Dyne aims to address the root cause of disease and deliver functional improvement for people living with conditions such as Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). The company advances a pipeline of therapeutics from discovery through clinical development with the mission of transforming the lives of patients with rare neuromuscular diseases.
Dyne Therapeutics: Strong DELIVER Data Strengthens The Bull Case (NASDAQ:DYN)
2 days ago
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
3 days ago
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
22 hours ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Dyne Therapeutics.
9% below the average for this role
150-patient Dyne trial focuses on myotonic dystrophy daily function
3 days ago
Research Scientist I/II, Oligonucleotide Chemistry
Diversity Employment
Senior Scientist, Discovery Chemistry
Sarepta Therapeutics
Senior Scientist I or II, Oligonucleotide Chemistry and Innovation
Novartis
Co-op: Small Scale Guide RNA Chemistry
Prime Medicine
Synthesis Scientist
Eli Lilly and Company
Senior Scientist I or II, Oligonucleotide Chemistry and Innovation
Novartis